Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jamie Findlow, Ray Borrow, David S. Stephens, Paul Liberator, Annaliesa S. Anderson, Paul Balmer & Luis Jodar. (2022) Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage. Expert Review of Vaccines 21:6, pages 753-769.
Read now
Read now
Jamie Findlow, Jay Lucidarme, Muhamed-Kheir Taha, Cynthia Burman & Paul Balmer. (2022) Correlates of protection for meningococcal surface protein vaccines: lessons from the past. Expert Review of Vaccines 21:6, pages 739-751.
Read now
Read now
Paul Balmer, Johannes Beeslaar, Jamie Findlow & Amit Srivastava. (2020) Understanding immunogenicity assessments for meningococcal serogroup B vaccines. Postgraduate Medicine 132:2, pages 184-191.
Read now
Read now
Articles from other publishers (9)
Elissa G. Currie & Scott D. Gray-Owen. (2021) Exploring the Ability of Meningococcal Vaccines to Elicit Mucosal Immunity: Insights from Humans and Mice. Pathogens 10:7, pages 906.
Crossref
Crossref
Shamez N Ladhani, Ray Borrow & Mary E Ramsay. (2021) Killing 2 Cocci With 1 Vaccine: Unleashing the Full Potential of an Adolescent Meningococcal B Immunization Program. Clinical Infectious Diseases 73:1, pages e238-e240.
Crossref
Crossref
Lucy A McNamara & Sarah Mbaeyi. (2021) First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants. The Lancet Infectious Diseases 21:5, pages 586-587.
Crossref
Crossref
Kimberly Davis, Marta Valente Pinto, Nick J Andrews, David Goldblatt, Ray Borrow, Helen Findlow, Jo Southern, Jo Partington, Emma Plested, Sima Patel, Ann Holland, Mary Matheson, Anna England, Bassam Hallis, Elizabeth Miller & Matthew D Snape. (2021) Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial. The Lancet Infectious Diseases 21:5, pages 688-696.
Crossref
Crossref
Alessia Biolchi, Sara Tomei, Laura Santini, Rita La Gaetana, Elena Mori, Patricia Novy, Rino Rappuoli, Rafik Bekkat-Berkani, Marzia Monica Giuliani & Mariagrazia Pizza. (2020) Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents. Pediatric Infectious Disease Journal 40:2, pages e66-e71.
Crossref
Crossref
Sydel R. Parikh, Helen Campbell, Julie A. Bettinger, Lee H. Harrison, Helen S Marshall, Federico Martinon-Torres, Marco Aurelio Safadi, Zhujun Shao, Bingqing Zhu, Anne von Gottberg, Ray Borrow, Mary E Ramsay & Shamez N Ladhani. (2020) The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. Journal of Infection 81:4, pages 483-498.
Crossref
Crossref
Chiara Azzari, Maria Moriondo, Francesco Nieddu, Valentina Guarnieri, Lorenzo Lodi, Clementina Canessa, Giuseppe Indolfi, Mattia Giovannini, Giuseppina Napoletano, Francesca Russo, Tatjana Baldovin, Silvia Cocchio, Silvia Ricci & Vincenzo Baldo. (2020) Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018). Vaccines 8:3, pages 469.
Crossref
Crossref
Catherine Isitt, Catherine A Cosgrove, Mary Elizabeth Ramsay & Shamez N Ladhani. (2020) Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Archives of Disease in Childhood 105:8, pages 784-790.
Crossref
Crossref
T. Tenenbaum, W. Hellenbrand & H. Schroten. (2019) Impfstoffe gegen Meningokokken für das KindesalterVaccines against meningococci for children. Monatsschrift Kinderheilkunde 167:3, pages 196-205.
Crossref
Crossref